U.S. Alzheimer’s-linked Imaging Market Size, Share & Trends Analysis Report By Imaging Modality (Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Single Photon Emission Computed Tomography), By End-use, And Segment Forecasts, 2025 - 2
Description
Market Size & Trends
The U.S. Alzheimer’s-linked imaging market size was estimated at USD 4.49 billion in 2024 and is projected to reach USD 6.90 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. Market growth is mainly driven by the rising number of Alzheimer’s cases across the country. According to the National Library of Medicine (NLH) (2024), around 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this number could reach 13.8 million by 2060 if no breakthrough occurs. Alzheimer’s is now the fifth-leading cause of death among older adults in the U.S., highlighting its growing public health impact.
As the prevalence of the disease increases, demand for early diagnosis and continuous monitoring is rising. This is creating strong opportunities for investment and innovation in Alzheimer’s-related imaging technologies and services. Government and public health agencies are also supporting this trend. For instance, the Centers for Disease Control and Prevention’s (CDC) Alzheimer’s disease Program promotes awareness, early detection, and diagnostic readiness. Together, these initiatives are helping expand diagnostic infrastructure, improve access to imaging services, and encourage technological advancements in brain-disease imaging across the U.S.
Furthermore, a study by Rush University highlighted significant regional differences in Alzheimer’s disease prevalence across the U.S., with the highest rates observed in states such as Florida and Maryland. These county-level variations are influenced by factors such as population age distribution, socioeconomic conditions, healthcare accessibility, and lifestyle habits.
Technological advancements continue to drive the growth of the U.S. Alzheimer’s-linked imaging industry. Currently used techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential methods for the diagnosis and monitoring of Alzheimer’s disease. MRI provides excellent anatomical imaging, PET allows visualization and quantification of amyloid-β plaques and tau tangles, and SPECT assesses cerebral blood flow and deficits in brain function. These techniques are routinely used to plan diagnosis and treatment in hospitals and outpatient imaging centers throughout the U.S.
AI-assisted diagnostics are transforming the U.S. Alzheimer’s-linked imaging market. For instance, Mayo Clinic’s StateViewer AI can detect nine types of dementia, including Alzheimer’s, from a single fluorodeoxyglucose positron emission tomography (FDG-PET) scan. By enhancing accuracy and reducing interpretation time, AI expands access to advanced diagnostics and boosts confidence in early, precise detection across clinical settings.
Furthermore, strong governmental support and strategic planning exist within the market. For instance, the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, oversees all federal activities aimed at addressing Alzheimer's disease (AD) and related dementias. The National Alzheimer's Project Act (NAPA) established the National Plan to Address Alzheimer's Disease, which aims to accelerate research, treatment, and support patients, families, and caregivers on various related topics. The plan's primary focus is on improving early detection, enhancing patient care and the caregiver experience, expanding effective care models, and advancing research in diagnosis and treatment. These initiatives reflect the U.S. government’s commitment to strengthening Alzheimer’s care infrastructure and research capacity, fostering wider adoption of advanced diagnostic and imaging technologies, and supporting growth in the Alzheimer’s-linked imaging market.
U.S. Alzheimer’s-linked Imaging Market Report Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Alzheimer’s-linked imaging market report based on imaging modality, and end use:
The U.S. Alzheimer’s-linked imaging market size was estimated at USD 4.49 billion in 2024 and is projected to reach USD 6.90 billion by 2033, growing at a CAGR of 5.1% from 2025 to 2033. Market growth is mainly driven by the rising number of Alzheimer’s cases across the country. According to the National Library of Medicine (NLH) (2024), around 6.9 million Americans aged 65 and older are currently living with Alzheimer’s dementia, and this number could reach 13.8 million by 2060 if no breakthrough occurs. Alzheimer’s is now the fifth-leading cause of death among older adults in the U.S., highlighting its growing public health impact.
As the prevalence of the disease increases, demand for early diagnosis and continuous monitoring is rising. This is creating strong opportunities for investment and innovation in Alzheimer’s-related imaging technologies and services. Government and public health agencies are also supporting this trend. For instance, the Centers for Disease Control and Prevention’s (CDC) Alzheimer’s disease Program promotes awareness, early detection, and diagnostic readiness. Together, these initiatives are helping expand diagnostic infrastructure, improve access to imaging services, and encourage technological advancements in brain-disease imaging across the U.S.
Furthermore, a study by Rush University highlighted significant regional differences in Alzheimer’s disease prevalence across the U.S., with the highest rates observed in states such as Florida and Maryland. These county-level variations are influenced by factors such as population age distribution, socioeconomic conditions, healthcare accessibility, and lifestyle habits.
Technological advancements continue to drive the growth of the U.S. Alzheimer’s-linked imaging industry. Currently used techniques, such as magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), are essential methods for the diagnosis and monitoring of Alzheimer’s disease. MRI provides excellent anatomical imaging, PET allows visualization and quantification of amyloid-β plaques and tau tangles, and SPECT assesses cerebral blood flow and deficits in brain function. These techniques are routinely used to plan diagnosis and treatment in hospitals and outpatient imaging centers throughout the U.S.
AI-assisted diagnostics are transforming the U.S. Alzheimer’s-linked imaging market. For instance, Mayo Clinic’s StateViewer AI can detect nine types of dementia, including Alzheimer’s, from a single fluorodeoxyglucose positron emission tomography (FDG-PET) scan. By enhancing accuracy and reducing interpretation time, AI expands access to advanced diagnostics and boosts confidence in early, precise detection across clinical settings.
Furthermore, strong governmental support and strategic planning exist within the market. For instance, the National Institute on Aging (NIA), part of the U.S. Department of Health and Human Services, oversees all federal activities aimed at addressing Alzheimer's disease (AD) and related dementias. The National Alzheimer's Project Act (NAPA) established the National Plan to Address Alzheimer's Disease, which aims to accelerate research, treatment, and support patients, families, and caregivers on various related topics. The plan's primary focus is on improving early detection, enhancing patient care and the caregiver experience, expanding effective care models, and advancing research in diagnosis and treatment. These initiatives reflect the U.S. government’s commitment to strengthening Alzheimer’s care infrastructure and research capacity, fostering wider adoption of advanced diagnostic and imaging technologies, and supporting growth in the Alzheimer’s-linked imaging market.
U.S. Alzheimer’s-linked Imaging Market Report Segmentation
This report forecasts revenue growth at the country level and analyzes the latest industry trends in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Alzheimer’s-linked imaging market report based on imaging modality, and end use:
- Imaging Modality Outlook (Revenue, USD Million, 2021 - 2033)
- Positron Emission Tomography
- Amyloid Positron Emission Tomography
- Tau Positron Emission Tomography
- FDG- Positron Emission Tomography
- Magnetic Resonance Imaging
- Structural Magnetic Resonance Imaging
- Advanced Magnetic Resonance Imaging
- Single Photon Emission Computed Tomography
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Imaging Centers
- Contract Research Organizations (CROs)
- Others
Table of Contents
125 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Segment Definitions
- 1.2.1. Imaging Modality
- 1.2.2. End Use
- 1.2.3. Estimates and forecasts timeline
- 1.3. Research Methodology
- 1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR’s internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
- 1.4.5.1. Data for primary interviews in North America
- 1.5. Information or Data Analysis
- 1.5.1. Data analysis models
- 1.6. Market Formulation & Validation
- 1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
- 1.8. List of Secondary Sources
- 1.9. List of Primary Sources
- 1.10. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Imaging Modality Outlook
- 2.2.2. End Use Outlook
- 2.3. Competitive Insights
- Chapter 3. U.S. Alzheimer’s-linked Imaging Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Increasing prevalence of Alzheimer’s disease
- 3.2.1.2. Technological advancements
- 3.2.1.3. Governmental support and strategic planning
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. High Equipment Costs
- 3.2.2.2. Limited Accessibility
- 3.3. U.S. Alzheimer’s-linked Imaging Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. U.S. Alzheimer’s-linked Imaging Market: Imaging Modality Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. U.S. Alzheimer-linked Imaging Market: Imaging Modality Movement Analysis
- 4.3. U.S. Alzheimer-linked Imaging Market by Imaging Modality Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 4.5. Positron Emission Tomography
- 4.5.1. Positron Emission Tomography Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.2. Amyloid Positron Emission Tomography (PET)
- 4.5.2.1. Amyloid Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.3. Tau Positron Emission Tomography
- 4.5.3.1. Tau Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.5.4. FDG- Positron Emission Tomography
- 4.5.4.1. FDG-Positron Emission Tomography (PET) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Magnetic Resonance Imaging (MRI)
- 4.6.1. Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.2. Structural Magnetic Resonance Imaging (MRI)
- 4.6.2.1. Structural Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.3. Advanced Magnetic Resonance Imaging (MRI)
- 4.6.3.1. Advanced Magnetic Resonance Imaging (MRI) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.7. Single Photon Emission Computed Tomography (SPECT)
- 4.7.1. Single Photon Emission Computed Tomography (SPECT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.8. Others
- 4.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. U.S. Alzheimer’s-linked Imaging Market: End Use Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. U.S. Alzheimer-linked Imaging Market: End Use Movement Analysis
- 5.3. U.S. Alzheimer-linked Imaging Market by End Use Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
- 5.5. Hospitals & Clinics
- 5.5.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Diagnostic Imaging Centers
- 5.6.1. Diagnostic Imaging Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Contract Research Organizations (CROs)
- 5.7.1. Contract Research Organizations (CROs) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Others
- 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Competitive Landscape
- 6.1. Market Participant Categorization
- 6.2. Key Company Profiles
- 6.2.1. GE Healthcare
- 6.2.1.1. Company overview
- 6.2.1.2. Financial performance
- 6.2.1.3. Product benchmarking
- 6.2.1.4. Strategic initiatives
- 6.2.2. Siemens Healthineers AG
- 6.2.2.1. Company overview
- 6.2.2.2. Financial performance
- 6.2.2.3. Product benchmarking
- 6.2.2.4. Strategic initiatives
- 6.2.3. Life Molecular Imaging (LMI)
- 6.2.3.1. Company overview
- 6.2.3.2. Financial performance
- 6.2.3.3. Product benchmarking
- 6.2.3.4. Strategic initiatives
- 6.2.4. Eli Lilly and Company
- 6.2.4.1. Company overview
- 6.2.4.2. Financial performance
- 6.2.4.3. Product benchmarking
- 6.2.4.4. Strategic initiatives
- 6.2.5. SOFIE Biosciences
- 6.2.5.1. Company overview
- 6.2.5.2. Financial performance
- 6.2.5.3. Product benchmarking
- 6.2.5.4. Strategic initiatives
- 6.2.6. Lantheus Holdings, Inc.
- 6.2.6.1. Company overview
- 6.2.6.2. Financial performance
- 6.2.6.3. Product benchmarking
- 6.2.6.4. Strategic initiatives
- 6.2.7. Jubilant Radiopharma
- 6.2.7.1. Company overview
- 6.2.7.2. Financial performance
- 6.2.7.3. Product benchmarking
- 6.2.7.4. Strategic initiatives
- 6.2.8. Brainreader A/S/ Neuroreader
- 6.2.8.1. Company overview
- 6.2.8.2. Financial performance
- 6.2.8.3. Product benchmarking
- 6.2.8.4. Strategic initiatives
- 6.2.9. Koninklijke Philips N.V.
- 6.2.9.1. Company overview
- 6.2.9.2. Financial performance
- 6.2.9.3. Product benchmarking
- 6.2.9.4. Strategic initiatives
- 6.2.10. Alzevita
- 6.2.10.1. Company overview
- 6.2.10.2. Financial performance
- 6.2.10.3. Product benchmarking
- 6.2.10.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.